FDA Authorizes Pfizer/BioNTech And Moderna's Bivalent COVID Shots For 6 Months Old

  • The FDA has authorized COVID-19 shots from Moderna Inc MRNA and Pfizer Inc PFEBioNTech SE BNTX targeting the original coronavirus and Omicron sub-variants for use in children as young as six months of age.
  • The amended authorization allows the use of Moderna's bivalent shot as a booster in children six months through 5 years of age, two months after their initial vaccination.
  • Pfizer/BioNTech's updated shot can now be given as a third dose to those aged six months through 4 years who have not completed their primary vaccination series or are yet to receive the third dose.
  • Related: Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims.
  • The agency said that children who have completed their initial three-dose vaccination with Pfizer's original shot are not yet eligible to receive the bivalent booster.
  • FDA said that data supporting Pfizer/BioNtech's bivalent shot as a booster for children aged six months - 4 years is expected in January.
  • Price Action: PFE stock is up 2.23% at $51.36, BNTX shares are up 3.78% at $168.78, and MRNA shares are up 1.73% at $182.09 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!